title: Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.
abstract: Self-emulsifying drug delivery systems (SEDDSs) represent a possible alternative to traditional oral formulations of lipophilic compounds. In the present study, a lipophilic compound, WIN 54954, was formulated in a medium chain triglyceride oil/nonionic surfactant mixture which exhibited self-emulsification under conditions of gentle agitation in an aqueous medium. The efficiency of emulsification was studied using a laser diffraction sizer to determine particle size distributions of the resultant emulsions. An optimized formulation which consisted of 25% (w/w) surfactant, 40% (w/w) oil, and 35% (w/w) WIN 54954 emulsified rapidly with gentle agitation in 0.1 N HCl (37 degrees C), producing dispersions with mean droplet diameters of less than 3 microns. The self-emulsifying preparation was compared to a polyethylene glycol 600 (PEG 600) solution formulation by administering each as prefilled soft gelatin capsules to fasted beagle dogs in a parallel crossover study. Pharmacokinetic parameters were determined and the absolute bioavailability of the drug was calculated by comparison to an i.v. injection. The SEDDS improved the reproducibility of the plasma profile in terms of the maximum plasma concentration (Cmax) and the time to reach the maximum concentration (tmax). There was no significant difference in the absolute bioavailability of WIN 54954 from either the SEDDS or the PEG formulations.
authors.affiliation: Sterling Research Group, Rensselaer, New York 12144.
authors.forename: S A
authors.initials: SA
authors.lastname: Charman
authors.forename: W N
authors.initials: WN
authors.lastname: Charman
authors.forename: M C
authors.initials: MC
authors.lastname: Rogge
authors.forename: T D
authors.initials: TD
authors.lastname: Wilson
authors.forename: F J
authors.initials: FJ
authors.lastname: Dutko
authors.forename: C W
authors.initials: CW
authors.lastname: Pouton
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002214:Capsules; D004285:Dogs; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005079:Excipients; D005780:Gelatin; D007275:Injections, Intravenous; D007555:Isoxazoles / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008055:Lipids / Q000737:chemistry*; D008297:Male; D010316:Particle Size; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004856:Postural Balance / Q000502:physiology
chemical_list: D002214:Capsules; D015507:Drugs, Investigational; D005079:Excipients; D007555:Isoxazoles; D008055:Lipids; C062554:Win 54954; D011092:Polyethylene Glycols; D005780:Gelatin